ClinicalTrials.gg
RecruitingNCT06477952DROSAUpdated Nov 5, 2026

DRonabinol Treatment of OSA

A Phase 1/2 interventional study of Dronabinol in Obstructive Sleep Apnea, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged Up to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by VA Office of Research and Development · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Nov 5, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
Up to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development — 7 open to participants now, 8 under way, none of them phase 3. Sleep Apnea, Obstructive · VA Office of Research and Development.

Planned enrollment
10th of 22
120 · median 92
Started
2025
the only one that year
Phase 1/2
2 of 24
2 open now
Registered
24th of 24
by date

Among the 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development, this one is the 10th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 1/2, and was the 24th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

7 of the 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: Up to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development, or all of them as a file.
02

Study summary

This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.

Read the detailed description

Obstructive sleep apnea (OSA), is a serious respiratory disorder that involves repetitive cessation of breathing during sleep. It is estimated that 15-20 million people in the United States suffer from OSAS, which has been linked to increased risk for hypertension, heart failure, depression, and diabetes. The current standard of care for OSA, positive airway pressure (PAP), involves a mechanical device with low patient tolerance and adherence. Upper airway surgical approaches are also an option but are invasive and often unsuccessful. Effective drug treatments for OSA remain to be identified.

This study will enroll up to 120 Veterans so that 45 Veterans may complete the two-week open-label Dronabinol treatment trials. The results of the study will be used to develop a prediction model for OSA severity reduction after 2-week Dronabinol treatment vs. pretreatment AHI. Participants clinical (age, sex, body mass index, comorbidity) and pretreatment polysomnographic characteristics (sleep architecture, respiratory disturbance, and endotypes; loop-gain, arousal threshold, upper airway collapsibility and compensation) will be used to develop a prediction model for improvement of OSA with Dronabinol treatment. This prediction model will be used for a randomized clinical trial after the completion of this trial.

03

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • OSA
  • sleep apnea
  • pharmacological treatment
  • Drug treatment
04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
Up to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. AHI 15-50 per hour on pre-treatment polysomnography

Exclusion criteria

Exclusion Criteria:

  1. Positive Airway Pressure (PAP) treatment of obstructive sleep apnea (OSA): use > 4 hours per day for 30% of days within 3 months of enrollment. PAP use will be determined from device download data
  2. Hypoglossal nerve stimulator (HNS) or oral appliance device treatment with use > 4 hours per day for 30% of days within 3 months of enrollment. HNS use will be determined by device download and oral appliance use by self-report
  3. History of upper airway surgery for OSA (except adenotonsillectomy)
  4. Central or mixed apneas >25% of respiratory events on diagnostic polysomnography
  5. Arterial oxygen saturation \< 75% for > 5% sleep time on pretreatment polysomnography
  6. > 45 kilograms per square meter (kg/m2)
  7. If post-bariatric surgery, weight must be stable ±5% (per electronic medical records) for at least 6 months before the first dose of the study drug
  8. Active enrollment in a weight loss program
  9. Shiftwork within 3 months of enrollment
  10. High-risk occupation: commercial driver and pilot
  11. Motor vehicle accident or near-miss incident within 1 year of enrollment
  12. Current drug or habitual alcohol use or positive urine drug screen
  13. Comorbid medical and psychiatric disorders:

    1. Primary sleep disorders: e.g., narcolepsy, restless legs syndrome
    2. Uncontrolled mood disorder or a diagnosis of schizophrenia
    3. Initiation of new antidepressant or antipsychotic medication within 3 months
    4. Identified as high-risk for suicide in electronic health records
    5. Uncontrolled medical disorders (coronary heart disease, arrhythmia, congestive heart failure, , chronic hypoxemic or hypercapnic respiratory failure, stroke within 6 months of enrollment, chronic liver or kidney disease, disorders)
  14. Use of sedative-hypnotic medications within 30 days of enrollment
  15. Complete blood count or liver function test values more than 1.5 times the
  16. Pregnancy
  17. Allergy to cannabinoids or sesame oil
  18. Average weekly alcohol consumption of more than 10 servings
  19. Participation in other protocols within 30 days of enrollment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Single group

    Open label Dronabinol treatment for two weeks.

    Drug: Dronabinol

Interventions

  • Open label Dronabinol treatment for two weeks.

    Also known as: Marinol

06

What researchers measure

Primary outcomes

  1. Apnea Hypopnea Index (AHI)

    The change in AHI after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

    Time frame: 2 weeks

Secondary outcomes

  1. T<90

    The change in time below 90% oxygen saturation (T\<90) after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

    Time frame: 2 weeks

Other outcomes

  1. Psychomotor Vigilance Test (PVT)

    The change in Lapses on Psychomotor Vigilance Test (PVT) after two weeks of Dronabinol treatment will be determined from before and after treatment PVT using a 10 minute protocol.

    Time frame: 2 weeks

  2. 24-hour Mean Arterial Blood Pressure (BP)

    The change in 24- hour mean arterial blood pressure after two weeks of Dronabinol treatment will be determined from before and after treatment 24-hiur ambulatory BP recording.

    Time frame: 2 weeks

  3. Sleep Efficiency

    The change in sleep efficiency after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

    Time frame: 2 weeks

  4. Rapid Eye Movement (REM) Sleep

    The change in REM sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

    Time frame: 2 weeks

  5. Slow Wave Sleep

    The change in slow wave sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

    Time frame: 2 weeks

  6. Treatment Satisfaction Questionnaire for Medication (TSQM)

    Patient reported treatment satisfaction. TSQM scores have a range of 0 to 100, with higher scores indicating higher satisfaction.

    Time frame: 2 weeks

  7. Epworth Sleepiness Scale (ESS)

    The change in Epworth Sleepiness Scale (ESS) will be measured after two weeks of Dronabinol treatment. ESS scores have a range of 0 to 24, with higher scores indicating greater sleepiness.

    Time frame: 2 weeks

  8. Functional Outcomes of Sleep Questionnaire (FOSQ)

    The change in Functional Outcomes of Sleep Questionnaire (FOSQ) will be measured after two weeks of Dronabinol treatment. FOSQ score ranges from 5-20, with higher scores indicating better functional status.

    Time frame: 2 weeks

  9. Pittsburgh Sleep Quality Index (PSQI)

    The change in Pittsburgh Sleep Quality Index (PSQI) will be measured after two weeks of Dronabinol treatment. The PSQI score ranges from 0 to 21. Higher scores indicate poorer sleep quality.

    Time frame: 2 weeks

  10. Insomnia Severity Index (ISI)

    The change in Insomnia Severity Index (ISI) will be measured after two weeks of Dronabinol treatment. ISI ranges from 0 to 28, with higher scores indicating greater sleep disturbance.

    Time frame: 2 weeks

  11. Post-Traumatic Stress Disorder; PTSD checklist (PCL-5)

    The change in Post-Traumatic Stress Disorder; PTSD checklist (PCL-5) will be measured after two weeks of Dronabinol treatment. PCL-5 scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity.

    Time frame: 2 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2026 → Mar 2027 and completion Dec 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2024
First posted
Jun 27, 2024
StartActual
Aug 25, 2025
Primary completionEst.
Mar 31, 2027was Dec 2026
CompletionEst.
Mar 31, 2027was Dec 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Mar 31, 2027
Nov 5, 2026
Study completion
Dec 31, 2026→Mar 31, 2027
Nov 5, 2026
Eligibility
2 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedPositive Airway Pressure (PAP) treatment of obstructive sleep apnea (OSA): use > 4 hours per day for 30% of days within 3 months of enrollment. PAP use will be determined from device download data
  • EditedBody mass index > 45 kilograms per square meter (kg/m2)
Nov 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedApnea hypopnea indexHypopnea Index (AHI)Time frame: 2 weeks
Nov 5, 2026
Secondary outcomes
3 edited
What changed in the outcomes
  • Editedother outcome24-hour mean arterial blood pressureMean Arterial Blood Pressure (BP)Time frame: 2 weeks
  • Editedother outcomeRapid eye movementEye Movement (REM) sleepSleepTime frame: 2 weeks
  • Editedother outcomeSlow wave sleepWave SleepTime frame: 2 weeks
Nov 5, 2026
Sponsor
Collaborators added: University of Illinois Chicago; collaborators removed: University of Illinois at Chicago
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Dec 31, 2026→Mar 31, 2027
    Study completion Dec 31, 2026→Mar 31, 2027
    Eligibility 2 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedPositive Airway Pressure (PAP) treatment of obstructive sleep apnea (OSA): use > 4 hours per day for 30% of days within 3 months of enrollment. PAP use will be determined from device download data
    • EditedBody mass index > 45 kilograms per square meter (kg/m2)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedApnea hypopnea indexHypopnea Index (AHI)Time frame: 2 weeks
    Secondary outcomes 3 edited
    What changed in the outcomes
    • Editedother outcome24-hour mean arterial blood pressureMean Arterial Blood Pressure (BP)Time frame: 2 weeks
    • Editedother outcomeRapid eye movementEye Movement (REM) sleepSleepTime frame: 2 weeks
    • Editedother outcomeSlow wave sleepWave SleepTime frame: 2 weeks
    Sponsor Collaborators added: University of Illinois Chicago; collaborators removed: University of Illinois at Chicago
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06477952
Collaborators
University of Illinois Chicago
Responsible party
Sponsor
First posted
Jun 27, 2024
Start date
Aug 25, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Bharati Prasad, MD
Contact
bharati.prasad@va.gov
(312) 996-8433
Karen M Lenehan
Contact
Karen.Lenehan@va.gov
(312) 569-6343
Bharati Prasad, MD
principal investigator · Jesse Brown VA Medical Center, Chicago, IL

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion